- Home
- GLQ vs UNCY Comparison
GLQ vs UNCY Comparison
Compare GLQ & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | UNCY |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.2M | 150.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLQ | UNCY |
|---|---|---|
| Price | $8.35 | $5.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 47.7K | ★ 795.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.14 | $3.72 |
| 52 Week High | $8.75 | $8.74 |
Technical Indicators
Market Signals| Indicator | GLQ | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 52.73 |
| Support Level | $8.02 | $5.28 |
| Resistance Level | $8.35 | $5.96 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 67.74 | 89.89 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.